Objective: To evaluate the impact of different peak GH cut-off limits after GHRH-Arg test, IGF1 measurement, or their combination in identifying patients with GH deficit (GHD). Design and patients: Totally, 894 normal subjects (used for determining IGF1 normative limits) and 302 patients with suspectedGHDwere included.Different peakGHcut-off limits (used by European (depending on body mass index (BMI)) or North American (4.1 mg/l) Endocrine Societies, by HypoCCs (2.5 mg/l), or with 95% specificity (based on BMI), Method 1, 2, 3, or 4 respectively) and IGF1 were considered. Methods: Peak GH after GHRH-Arg and IGF1. Results: Different peak GH cut-off limits recognized different proportions of GHD (range, 24.8-62.9%). Methods1 and 2with high sensitivity recognized a higher proportion (95.5 and 92.5% respectively) ofGHD among patients with three (T) pituitary hormone deficits (HD), whereas Method 4 (with high specificity) identified 96.7% normal subjects among those without pituitary HD; on the contrary, Method 4 identified only 75% GHD among patients with THD, whereas Method 1 recognized a high proportion (40%) of GHD among subjectswithoutHD.Of the total patients,82%with THDand 84.5%withoutHDwere recognized as GHD or normal respectively by IGF1. Among the remaining patientswith THD and normal IGF1, 75%was recognized as GHD byMethod 1; among patients without HD and abnormal IGF1, 87.5% was identified as normal by Method 4. Overall, combination of IGF1 and Method1 orMethod 4 identified 95.5%GHDamong patients with THD and 98.1% normal subjects among those without HD. Conclusions: Single peakGHcut-offs have limits to sharplydifferentiateGHDfromnormal subjects; IGF1may be used for selecting patients to be submitted to the GHRH-Arg test; the peak GH cut-off limits to be used for identifying healthy or diseased patients depend mainly on the clinical context.

Impact of different cut-off limits of peak GH after GHRH-arginine stimulatory test, single IGF1 measurement, or their combination in identifying adult patients with GH deficiency

Rossi Giuseppe
2011

Abstract

Objective: To evaluate the impact of different peak GH cut-off limits after GHRH-Arg test, IGF1 measurement, or their combination in identifying patients with GH deficit (GHD). Design and patients: Totally, 894 normal subjects (used for determining IGF1 normative limits) and 302 patients with suspectedGHDwere included.Different peakGHcut-off limits (used by European (depending on body mass index (BMI)) or North American (4.1 mg/l) Endocrine Societies, by HypoCCs (2.5 mg/l), or with 95% specificity (based on BMI), Method 1, 2, 3, or 4 respectively) and IGF1 were considered. Methods: Peak GH after GHRH-Arg and IGF1. Results: Different peak GH cut-off limits recognized different proportions of GHD (range, 24.8-62.9%). Methods1 and 2with high sensitivity recognized a higher proportion (95.5 and 92.5% respectively) ofGHD among patients with three (T) pituitary hormone deficits (HD), whereas Method 4 (with high specificity) identified 96.7% normal subjects among those without pituitary HD; on the contrary, Method 4 identified only 75% GHD among patients with THD, whereas Method 1 recognized a high proportion (40%) of GHD among subjectswithoutHD.Of the total patients,82%with THDand 84.5%withoutHDwere recognized as GHD or normal respectively by IGF1. Among the remaining patientswith THD and normal IGF1, 75%was recognized as GHD byMethod 1; among patients without HD and abnormal IGF1, 87.5% was identified as normal by Method 4. Overall, combination of IGF1 and Method1 orMethod 4 identified 95.5%GHDamong patients with THD and 98.1% normal subjects among those without HD. Conclusions: Single peakGHcut-offs have limits to sharplydifferentiateGHDfromnormal subjects; IGF1may be used for selecting patients to be submitted to the GHRH-Arg test; the peak GH cut-off limits to be used for identifying healthy or diseased patients depend mainly on the clinical context.
2011
Istituto di Fisiologia Clinica - IFC
File in questo prodotto:
File Dimensione Formato  
prod_312593-doc_89332.pdf

solo utenti autorizzati

Descrizione: Impact of different cut-off limits of peak GH after GHRHarginine stimulatory test, single IGF1 measurement, or their combination
Dimensione 197.86 kB
Formato Adobe PDF
197.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/254309
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 13
social impact